

1

2

3

4 Effect of fosfomicin, *Cynara scolymus* extract, deoxynivalenol and their
5 combinations on intestinal health of weaned piglets

6

7 Guadalupe Martínez^{1,2,3¶*}, Susana N. Diéguez^{1,2,4¶}, María B. Fernández Paggi^{1,2,5}, María
8 B. Riccio¹; Denisa S. Pérez Gaudio^{1,2,3}, Julieta M. Decundo^{1,2,3}, Agustina Romanelli^{1,2,3},
9 Fabián A. Amanto⁵, María O. Tapia^{1,2,3}; Alejandro L. Soraci^{1,2,3¶*}

10

11 ¹Área Toxicología, Departamento de Fisiopatología, Facultad de Ciencias Veterinarias,
12 Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Buenos
13 Aires, Argentina.

14 ²Centro de Investigación Veterinaria de Tandil (CIVETAN), UNCPBA-CICPBA-
15 CONICET, Facultad de Ciencias Veterinarias, Campus Universitario, Tandil, Buenos
16 Aires, Argentina.

17 ³Consejo Nacional de Investigaciones Científicas-CONICET, Buenos Aires, Argentina

18 ⁴Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA),
19 Buenos Aires, Argentina.

20 ⁵Área Producción Porcina, Departamento de Producción Animal, Facultad de Ciencias
21 Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil,
22 Buenos Aires, Argentina.

23

24 *Corresponding author

25 E-mail: guadam@vet.unicen.edu.ar

26

27 ¶These authors contributed equally to this work.

28 **Abstract**

29 Intestinal health of weaning piglets was studied after oral treatments with
30 fosfomycin (FOS), *Cynara scolymus* extract (CSE), deoxynivalenol (DON) and their
31 combinations. Piglets were divided in groups and received different treatments during
32 15 days, namely DON (1mg/kg of feed), FOS administered into the drinking water (30
33 mg/kg b.w.), CSE (300 g/ton of feed) and all possible combinations including a control
34 group that received clean balanced diet. At day 15, three piglets from each group were
35 euthanized and gastrointestinal tract samples were immediately taken to evaluate pH,
36 bacteriology (enterobacteria and lactic acid bacteria), volatile fatty acids concentration
37 (VFAs), disaccharidases activity (lactase, sucrase and maltase), histology (intestinal
38 absorptive area [IAA] and goblet cells count) and adherence of bacteria to intestinal
39 mucus. Animals receiving FOS and CSE treatments exhibited evident beneficial
40 intestinal effects compared to animals receiving diets free from these compounds. This
41 was revealed by a lower enterobacteria population together with a lower E/L, an
42 enhanced production of butyric acid, an increased enzymatic activity (particularly
43 maltase), and a greater IAA and goblet cells count along with an increase in pathogenic
44 bacteria adherence to intestinal mucus. Interactions between both treatments resulted in
45 similar beneficial effects as their individual administration. On the contrary, DON
46 produced detrimental effects on intestinal health as a decrease was observed on volatile
47 fatty acids production, enzymatic activity and goblet cells count in animals receiving
48 diets containing sub- toxic concentrations of this mycotoxin. The knowledge of the
49 intestinal effects of these compounds contributes to understand the physiological and
50 pathological gut changes and their potential productive consequences.

52 Introduction

53 Weaning is considered one of the most critical periods of pig production because
54 of its highly negative impact on health and productive performance of piglets, mainly in
55 the first post-weaning days. During this period, the animals are exposed to
56 physiological, immunological, microbiological, social, environmental and nutritional
57 factors that lead to post-weaning stress (1–3). In order to overcome this situation a
58 common, though not rational practice, has been the prophylactic use of antibiotics in
59 intensive pig production. Fosfomycin ((cis 1-2 epoxy propyl) phosphonic acid, FOS) is
60 a broad spectrum bactericide antibiotic, widely used in pig farms in Central and South
61 America, South Africa and Southeast Asia. At weaning FOS is indicated for the
62 treatment of several bacterial infections (*Haemophilus parasuis*, *Streptococcus suis*,
63 *Pasteurella multocida*, *Bordetella bronchiseptica*, *Staphylococcus hyicus*, *Escherichia*
64 *coli*, etc.) associated to stress (4).

65 In addition, vegetable extracts, particularly *Cynara scolymus* extract (CSE), have
66 long been used in different species for their hepatoprotective and digestive roles,
67 exerting a choleric– cholagogue effect, increasing bile concentrations at small
68 intestine level and thus enhancing fat and lipophilic vitamins absorption. In animal
69 production, these compounds are used as feed additives to improve zootechnical
70 parameters (5–8) and they have shown further beneficial consequences on intestine and
71 liver functions. Nowadays enteroprotective, trophic, antitoxic and antimicrobial effects
72 are ascribable to bile action (9–12). CSE is used in intensive pig and avian productions.
73 It is obtained from the leaves of the plant and contains caffeolquinic acid derivatives
74 which are known for their choleric– cholagogue effect in different species (7,13,14),
75 including pigs (15).

76 Among weaning stress factors, the presence of anti-nutritional compounds in
77 feed, such as mycotoxins, negatively influences the productive performance of animals.
78 Deoxynivalenol (DON) is a mycotoxin produced by *Fusarium* species, being pigs the
79 most susceptible species to its toxic effects (16,17). Formerly DON was also called
80 vomitoxin, referring to its emetic effect (18,19). Other clinical signs that have been
81 described include reduction in feed intake and complete feed refusal,
82 immunosuppression, haemorrhage and eventually, circulatory shock (20–22). However
83 there is little information on the possible subclinical effects associated to the ingestion

84 of feed contaminated with low DON concentrations, which is highly likely to occur
85 (19,23,24).

86 In the productive reality, in innumerable situations, but mostly during weaning,
87 antibiotics, natural extracts and mycotoxins coexist in the animals' diet, and
88 consequently in the gut, regardless the potential interactions among them.

89 The aim of this study was to evaluate the effect of FOS, CSE, DON and their
90 interactions on the intestinal health of weaning piglets.

91

92 **Materials and methods**

93 **Animals**

94 The study was carried out according to guidelines of the Animal Welfare
95 Committee of the Faculty of Veterinary Sciences UNCPBA, Argentina, for animal
96 handling and experimentation. One hundred and sixty, healthy, 21 days old weaned
97 piglets (6.26 ± 0.4 kg body weight [b.w.]) of the same genetic line from a commercial
98 farm were used. Piglets were housed in an environmentally controlled barn ($22 \pm 5^\circ\text{C}$;
99 light: dark cycle 12:12 h; relative humidity 45-65%), given free access to feed
100 (commercial feed: 3.0 Kcal/Kg of metabolizable energy) and water, and were checked
101 daily.

102 **Antibiotic, natural extract and mycotoxin**

103 *Fosfomicin (FOS)*: Calcium fosfomicin was provided by Bedson S.A.
104 laboratory (Fosbac[®], Pilar, Buenos Aires, Argentina). The antibiotic dose was 30 mg/kg
105 b.w. administered via drinking water. Water consumption was measured by a water
106 flow meter installed at the entrance pipeline of the weaning room two days before the
107 beginning of the trial. Medicated water was prepared daily at 8.00 am, considering
108 water consumption and mean piglets weight.

109 *Cynara scolymus extract (CSE)*: This natural extract was provided by Bedson
110 S.A. laboratory (Bedgen40[®], Pilar, Buenos Aires, Argentina). Three hundred grams of
111 CSE were uniformly mixed with one ton of feed (15 mg/kg b.w.).

112 *Deoxynivalenol (DON)*: The mycotoxin was produced in our laboratory by
113 growing *Fusarium graminearum* NRRL 28063 in corn at 25°C for 25 days. For DON
114 quantification, samples of ground corn were extracted twice with water/acetonitrile and
115 then with hexane by liquid-liquid extraction. Extracts were passed through DONPREP
116 columns (R-Biopharm, Acre Road, Glasgow, Scotland) and evaporated to dryness at
117 40°C. The dry extract was reconstituted with MilliQ water and filtered through 0.22 µm
118 nylon membranes before Injection into HPLC UV/VIS for quantification. A Gilson
119 HPLC system equipped with a Gilson 151 UV-Vis detector and Gilson 712 software
120 was used for data analysis (Gilson, Inc., Middleton, USA). The column was a C18; 250
121 mm × 3.00 mm Sinergy Hydro RP 4 µm (Phenomenex, Torrance, United States)
122 maintained in at 35°C. The mobile phase was water: acetonitrile (90:10) at 0.5 ml/min
123 flow rate. DON was detected at 222 nm and its retention time was 8.7 min.

124 Convenient aliquots of ground contaminated corn were uniformly mixed with
125 feed in order to obtain 1 mg DON/ Kg (50 µg/kg b.w.).

126 **Experimental groups**

127 Weaning piglets were randomly assigned to one of eight groups, which were
128 subjected to different treatments for a 15 days period. The dietary treatments were as
129 follows: A) balanced diet containing DON (1mg/kg of feed), B) balanced diet and FOS
130 administered into the drinking water (30 mg/kg b.w.), C) balanced diet containing CSE
131 (300 g/ton of feed), D) balanced diet containing DON (1mg/kg of feed) and FOS (30
132 mg/kg b.w.) into the drinking water, E) balanced diet containing DON (1mg/kg of feed)
133 plus CSE (300 g/ton of feed), F) balanced diet containing CSE (300 g/ton of feed) and
134 FOS (30 mg/kg b.w.) into the drinking water, G) balanced diet containing DON
135 (1mg/kg of feed) plus CSE (300 g/ton of feed) and FOS (30 mg/kg b.w.) into the
136 drinking water and, H) balanced diet without FOS, CSE or DON.

137 After 15 days of treatment, three piglets of each group were randomly selected
138 and euthanized for sampling of the gastrointestinal tract.

139 **pH determination**

140 As soon as each sample was obtained, pH was measured with a pH meter (UP-
141 25, Denver Instrument Company, Denver, Colorado, EE. UU.) in the following portions

142 of the gastrointestinal tract: caudal portion of the stomach, ileum (15 cm proximal to
143 ileocaecal valve), caecum and colon (20 cm distal from caecum).

144 **Enterobacteriaceae/Lactic acid bacteria ratio (E/L)**

145 The E/L has traditionally been used to determine balance of intestinal microbiota
146 in pigs (25). It has been demonstrated that a greater resistance to gastrointestinal
147 diseases is acquired when animals show a lower E/L (26–28).

148 The intestinal contents from ileum (15 cm proximal to the ileocaecal valve),
149 caecum and colon (20 cm distal from caecum) were collected and kept at 4°C until
150 arrival to the laboratory. One g of sample was diluted in 9 ml of peptone water and
151 homogenized by continuous agitation. Counting of viable bacteria was performed by
152 plating serial 10-fold dilutions (in 1% peptone water) onto MRS agar (Britania S.A.) for
153 *Lactic acid bacteria* (LAB) representative of beneficial bacteria in pigs, and onto Mac
154 Conkey agar (Britania S.A.) for *Enterobacteriaceae* representative of commensal Gram
155 negative bacteria (29–32). Colonies were counted, log transformed and expressed as
156 colony forming units per gram of digesta (CFU/g).

157 **Volatile fatty acids (VFAs)**

158 The caecal content was immediately diluted with phosphoric acid (in a 4:1
159 proportion) for preservation and kept at -70°C until analyzed. Concentrations of VFAs
160 were determined using gas liquid chromatography according to the method described by
161 Jouany (33). A Shimadzu chromatograph (Model GC–17A, Kyoto, Japan) with a
162 19091N-133 Innowax 30M column (Agilent, Santa Clara, CA, USA) was used. A
163 mixture of 10 mM Supelco VFAs (C2 to C10) and 2-ethyl-butyric acid (Fluka) as
164 internal standard were used to build calibration curves.

165 **Disaccharidases activity**

166 The digestive function of the intestine can be evaluated by the activity of
167 disaccharidases present in the microvilli or brush border of the enterocytes (34,35). The
168 evaluation of these enzymes gives information on the physio pathological status of the
169 intestinal mucosa (36).

170 The four portions of the small intestine (duodenum, proximal jejunum, medium
171 jejunum and ileum) were opened along the mesenteric border and washed with saline

172 solution to eliminate the mucus and remaining intestinal contents. The mucosa was
173 scraped off with a scalpel and 1.000 g of this material was weighed. Then, saline
174 solution (2 ml) was added to the intestinal mucosa and it was ground with a dispersing
175 instrument (Ultra-Turrax®) and a Potter homogenizer. Samples were then cold-
176 centrifuged at 4°C and 6630 rpm for 10 min. The supernatant was used as crude enzyme
177 solution and it was stored at – 20°C until analysis. The protein concentration of each
178 homogenate was determined by Bradford method using bovine serum albumin as
179 standard (37). The activity of sucrase, lactase and maltase was determined by
180 quantification of released glucose, according to Dahlqvist method (38). Briefly, the
181 homogenate supernatants were diluted, added to an equal volume of 0.1 M sodium
182 maleate buffer (pH 6.0) containing 56 mM lactose, sucrose or maltose, and incubated
183 for 1 h at 37°C. Then, the mixtures were added to the glucose oxidase–peroxidase
184 reagents (Sigma Chemical Company, USA) containing O-dianisidine as chromogen.
185 The absorbance was measured using a spectrophotometer (Dupont, Sorvall Instruments)
186 at 450 nm. The activity of disaccharidases was expressed as U/mg protein. One U is
187 defined as the amount of enzyme that hydrolyses 1 mmol of lactose, sucrose or maltose
188 in 1 min under the standard assay conditions.

189 **Histological study**

190 Different measures on villi and crypts can be correlated to nutrient absorption
191 capacity, possible structural alterations of intestinal mucosa and consequent productive
192 yield (34,39–47).

193 Samples of medium jejunum (1.5 m from stomach) and ileum (20 cm proximal
194 to ileocaecal valve) were washed with saline solution to remove the intestinal content,
195 transversally cut and fixed in Bouin solution (75% saturated picric acid, 20%
196 formaldehyde and 5% acetic acid). After 24 h of fixation, the samples were embedded
197 in paraffin and stained with haemotoxylin and eosin (H&E) and periodic acid-Schiff
198 (PAS).

199 The intestinal mucosa was examined under light microscope and measured by
200 the Image Analysis Software (ToupTek™ ToupView™). The length of villi and width
201 of villi and crypts were measured in H&E- stained sections. The goblet cells count in
202 villi and crypts (expressed as goblet cells/ 100 villi or crypts) was determined using
203 PAS staining (48,49). Means were calculated for each group. The mathematical model

204 proposed by Kisielinski *et al* was used to estimate the intestinal absorptive area (IAA)
205 using the following equation (50):

$$206 \quad IAA = (villusW \times villusL) + \frac{villusW^2}{2} + \frac{cryptW^2}{2} - \frac{villusW^2}{2} / \frac{villusW}{2} + \frac{cryptW^2}{2}$$

207 being, *IAA*= intestinal absorptive surface area, *villusW*= villi mean width, *villusL*= villi
208 mean length, and *cryptW*= crypts mean width.

209 Goblet cells count was used as index of the secretory capacity and the
210 production of protective intestinal mucus (51).

211 **Adherence of bacteria to intestinal mucus**

212 Mucus quality has been evaluated by its ability to adhere *E. coli*, since bacterial
213 adhesion is associated with the protective and antimicrobial functions of mucus favoring
214 bacterial elimination by the rapid removal of mucus by peristaltic movements (52,53).
215 The interaction between the glycoproteins of the outer layer of the intestinal mucus and
216 *E. coli* would prevent the attachment of bacteria to epithelial cells and subsequent
217 damage (51,53–58).

218 Ileum samples (15 cm proximal to ileocaecal valve) were opened along the
219 mesenteric border. The mucus was carefully scraped off with a scalpel (leaving
220 intestinal mucosa intact), collected into sterile tubes and kept at -70°C until analyzed.

221 The adherence of bacteria to the intestinal mucus was analyzed according to Bai
222 *et a.* (59). One hundred milligrams of mucus were diluted with 1.5 ml of saline solution
223 and centrifuged (12.000 rpm, 10 min, 4°C) to remove cell debris and bacteria. The
224 supernatant was sterilized by filtration (13 mm x 0.22 µm nylon filter membranes) and
225 the filtered solution was defined as the original crude mucus that contained
226 glycoproteins responsible for bacteria adherence. A concentration of 10³ CFU/ml of
227 *Escherichia coli* O157:H7 was incubated with supernatant containing crude mucus for
228 30 min, at 37°C under continuous agitation. Then the tubes were centrifuged (12.000
229 rpm, 10 min, 4°C) and pellets (with adhered and not adhered bacteria) were resuspended
230 in 400 µl saline solution and further centrifuged (2000 rpm, 4°C, 2 min). Two fractions
231 were obtained, the pellet which contained adhered bacteria and the supernatant which
232 contained not adhered bacteria. Aliquots from pellet and supernatant were spread on
233 Mac Conkey Agar with Sorbitol (Britania S.A.) and incubated under aerobic condition

234 for 24 h at 37 °C for colonies count. Results were expressed as percentage of adhered
235 bacteria to the intestinal mucus.

236 **Statistical analyses**

237 A 2x2x2 factorial arrangement was used to evaluate interactions between FOS (0
238 vs. 30 mg/kg b.w.), CSE (0 vs. 300 g/ton of feed) and DON (0 vs. 1 mg/kg feed) on the
239 intestinal health of weaned piglets. The response variables (pH, intestinal bacteria,
240 VFAs, disaccharidases activity, IAA, goblet cells and percentage of adhered bacteria to
241 intestinal mucus) were subjected to analysis of variance (ANOVA) by GLM procedure
242 of SAS V9.3 (SAS Institute Inc., Cary, NC, USA). Differences between treatments were
243 declared significant when $p < 0.05$. When significant interactions were observed,
244 contrasts were used to compare the different levels of each treatment. Data are presented
245 in tables as means and mean standard error (SEM).

246

247 **Results**

248 **pH**

249 pH values are shown in Table 1. No statically significant differences on pH were
250 found neither in gastrointestinal (GI) portions studied for groups treated with CSE and
251 DON nor in interactions between the different factors. In FOS treated groups, no
252 statically significant effects were found in caudal portion of stomach and ileum, but
253 piglets that received FOS showed a lower pH ($p < 0.01$) in caecum and colon. The mean
254 caecal pH was 5.51 ± 0.33 in FOS treated groups and 6.90 ± 0.29 in FOS free groups. The
255 mean pH in the colon was 6.21 ± 0.30 in FOS treated groups and 7.36 ± 0.26 in FOS free
256 groups.

Table 1. Effect of fosfomycin (FOS), *C. scolyms* extract (CSE), deoxynivalenol (DON) and their combinations on the gastrointestinal pH of weaned piglets¹

	FOS (mg/kg)				<i>p</i> - value				
	0		30						
pH	CSE (g/ton)		300		FOS				
	0	1	0	1					
stomach	4.08 ± 0.12	3.69 ± 0.34	3.34 ± 0.54	2.98 ± 0.34	3.27 ± 0.28	3.18 ± 0.37	4.15 ± 0.82	3.34 ± 0.06	NS
ileum	7.48 ± 0.14	7.29 ± 0.15	6.68 ± 0.99	7.51 ± 0.17	6.75 ± 0.90	6.27 ± 0.95	6.83 ± 0.72	7.92 ± 0.32	NS
caecum	6.77 ± 0.51	7.69 ± 0.29	6.40 ± 0.69	6.73 ± 0.52	5.70 ± 0.06	5.18 ± 0.11	4.97 ± 0.25	6.19 ± 1.00	0.0041
mean pH in FOS free or treated groups		6.90 ± 0.29				5.51 ± 0.33			
mean pH in FOS free or treated groups	7.78 ± 0.28	7.63 ± 0.25	6.42 ± 0.74	7.62 ± 0.07	6.40 ± 0.75	6.24 ± 0.93	5.16 ± 0.35	7.05 ± 0.96	0.0081
		7.36 ± 0.26				6.21 ± 0.30			

NS= not significant (*p* > 0.05).

¹ No significant effect of CSE and DON on the gastrointestinal pH were detected. Interaction between the different factors was not significant (*p* > 0.05).

258 **Enterobacteriaceae, lactic acid bacteria and E/L**

259 There was no effect of none of the treatments on the studied bacteria at ileum
260 level. LAB counts from caecum and colon did not show any significant differences
261 among treatments and effects of DON on *Enterobacteriaceae* in these intestinal portions
262 were neither detected. In caecum and colon, FOS and CSE treated groups showed lower
263 *Enterobacteriaceae* population and E/L regardless the presence of DON (Table 2). A
264 significant antagonistic interaction was observed between FOS and CSE on
265 *Enterobacteriaceae* count ($p= 0.0004$) and consequently on the E/L ($p= 0.0016$) at
266 caecum level. In this case, the effect of both treatments was less pronounced than the
267 effect they produced as individual factors. An indifferent interaction was observed for
268 *Enterobacteriaceae* count ($p= 0.0004$) and E/L ($p= 0.0114$) at colon level when FOS
269 and CSE were combined, i.e., the effect produced by the combination of FOS and CSE
270 was similar to the one observed when they were administered individually.

Table 2. Effect of the interaction between fosfomycin (FOS) and *C. scolyimus* extract (CSE) on the intestinal bacteria of weaned piglets¹

Item	CSE (g/ton)			FOS (mg/kg)			p- value	
	0	300	300	0	300	300	FOS x CSE	FOS x CSE
<i>Enterobacteriaceae</i> (log₁₀ CFU/g)								
caecum	6.21 ± 0.55	2.93 ± 0.32	2.42 ± 0.84	4.35 ± 0.62	0.0071	0.0331	0.0004	
colon	6.67 ± 0.40	2.74 ± 0.37	2.53 ± 0.86	3.39 ± 0.48	0.0055	0.0136	0.0004	
<i>Lactic acid bacteria</i> (log₁₀ CFU/g)								
caecum	7.54 ± 0.30	6.83 ± 0.14	6.52 ± 0.27	7.45 ± 0.50	NS	NS	NS	
colon	7.23 ± 0.45	7.11 ± 0.27	6.72 ± 0.19	8.03 ± 0.33	NS	NS	NS	
<i>E/L</i>								
caecum	0.82 ± 0.06	0.43 ± 0.04	0.37 ± 0.13	0.60 ± 0.09	0.0106	0.0313	0.0016	
colon	0.96 ± 0.11	0.39 ± 0.06	0.38 ± 0.13	0.44 ± 0.07	0.0253	0.0337	0.0114	

NS= not significant ($p > 0.05$).

¹ Effects of mycotoxin treatments on the studied intestinal bacteria were not significant.

271

272 Volatile fatty acids

273 Concentrations of VFAs were not modified in FOS treated groups and
 274 interactions between different factors were not significant ($p > 0.05$). CSE treated

275 groups increased the concentrations of butyric acid ($p= 0.033$). For DON treated groups
 276 lower acetic ($p= 0.0104$) and butyric ($p= 0.0001$) acids and lower total VFAs
 277 concentrations ($p= 0.0021$) were detected (Table 3).

Table 3. Effect of fosfomycin (FOS), *C. scolyimus* extract (CSE) and deoxynivalenol (DON) on VFAs (mmol/L) in the caecum of weaned piglets¹

VFAs	FOS (mg/kg)		p - value	CSE (g/ton)		p - value	DON (mg/kg)		p - value
	0	30		0	300		0	1	
Acetic acid	49.71 ± 4.5	60.35 ± 7.31	NS	50.29 ± 4.75	58.77 ± 6.88	NS	62.35 ± 5.55	43.01 ± 4.33	0.0104
Propionic acid	13.62 ± 1.27	16.44 ± 1.60	NS	13.95 ± 1.30	15.79 ± 1.60	NS	17.74 ± 1.10	10.84 ± 1.16	NS
Butyric acid	5.87 ± 0.60	6.78 ± 1.03	NS	5.83 ± 0.65	6.76 ± 0.93	0.033	8.00 ± 0.65	3.92 ± 0.36	0.0001
Total VFAs	71.49 ± 6.42	85.53 ± 9.69	NS	72.55 ± 6.72	83.07 ± 9.25	NS	90.76 ± 7.14	59.26 ± 5.81	0.0021

NS= not significant ($p > 0.05$).

¹ Interaction between the different factors was not significant ($p > 0.05$).

278

279 **Disaccharidases activity**

280 There were not significant interactions between FOS, CSE and DON on
281 disaccharidases activity ($p > 0.05$).

282 It was found that the activity of maltase in the different intestinal regions in
283 piglets from FOS treated groups was significantly higher ($p < 0.05$) than that observed in
284 FOS free groups. FOS treatments also increased sucrose and lactase activity in proximal
285 and medium jejunum and ileum though this effect was not statistically significant.
286 Treatments with CSE produced higher maltase activity in ileum ($p = 0.0020$). However,
287 an effect on the activity of sucrose and lactase was not observed. DON showed negative
288 effects for all enzymes in all intestinal portions, being enzymatic activity lower for pigs
289 fed diets supplemented with DON when compared to those without DON
290 supplementation. P value < 0.05 was observed for maltase and lactase activity in
291 duodenum and proximal jejunum, sucrose and lactase in medium jejunum and maltase
292 in the ileum (Table 4).

Table 4. Effect of fosfomycin (FOS), the *C. scolyms* extract (CSE) and deoxyvalenol (DON) on disaccharidases activity

Item	FOS (mg/kg)		p - value	CSE (g/ton)		p - value	DON (mg/kg)		p - value
	0	30		0	300		0	30	
<u>Duodenum</u>									
Maltase	1427.85 ± 169.23	2422.91 ± 338.39	0.0008	1951.87 ± 350.73	1862.65 ± 246.43	NS	2462.37 ± 339.66	1391.43 ± 147.09	0.0004
Sucrase	37.02 ± 15.26	36.86 ± 8.85	NS	41.32 ± 15.17	32.90 ± 10.07	NS	41.69 ± 10.17	32.56 ± 14.43	NS
Lactase	86.84 ± 28.70	88.19 ± 27.68	NS	72.60 ± 18.06	101.23 ± 34.11	NS	141.09 ± 33.98	38.01 ± 8.36	0.0092
<u>Proximal jejunum</u>									
Maltase	1964.33 ± 232.52	3419.02 ± 456.61	0.0028	2727.34 ± 465.01	2602.81 ± 362.69	NS	3420.65 ± 461.72	1962.83 ± 223.01	0.0028
Sucrase	89.26 ± 29.52	133.11 ± 51.55	NS	133.87 ± 28.64	88.55 ± 49.20	NS	145.62 ± 53.67	77.71 ± 23.98	NS
Lactase	162.66 ± 49.17	257.84 ± 91.37	NS	214.62 ± 55.72	202.56 ± 84.92	NS	324.52 ± 93.05	101.12 ± 22.84	0.041
<u>Medium jejunum</u>									
Maltase	2712.30 ± 293.58	4333.48 ± 493.03	0.0064	3854.78 ± 549.21	3154.17 ± 349.49	NS	4038.04 ± 432.94	2985.01 ± 440.51	NS
Sucrase	164.87 ± 48.53	284.39 ± 66.33	NS	259.65 ± 63.40	187.70 ± 55.14	NS	319.49 ± 69.41	132.47 ± 34.25	0.0147
Lactase	201.64 ± 62.08	342.47 ± 79.00	NS	316.65 ± 72.98	225.47 ± 71.34	NS	407.83 ± 80.99	141.30 ± 39.20	0.0105
<u>Ileum</u>									
Maltase	1047.08 ± 129.29	1464.89 ± 265.51	0.0337	947.73 ± 122.61	1524.46 ± 239.42	0.002	1623.23 ± 259.01	900.92 ± 75.58	0.0007
Sucrase	14.20 ± 9.13	59.01 ± 45.49	NS	15.72 ± 9.81	54.16 ± 42.12	NS	57.68 ± 45.56	15.42 ± 9.34	NS
Lactase	10.52 ± 3.42	18.26 ± 5.51	NS	14.16 ± 4.36	14.30 ± 4.87	NS	15.69 ± 4.86	12.89 ± 4.42	NS

NS= not significant ($p > 0.05$).

¹ Interaction between the different factors was not significant ($p > 0.05$).

294 **Intestinal absorptive area and goblet cells**

295 There was an evident increase in the IAA of medium jejunum in the presence of
296 FOS, CSE and the combination of both factors ($p < 0.05$). The co-administration of FOS
297 and CSE showed an indifferent type interaction at this level. IAA of ileum increased in
298 piglets that received CSE and an antagonistic interaction between FOS and CSE was
299 detected ($p < 0.05$). The IAA of medium jejunum and ileum was not affected by the
300 treatments with DON ($p > 0.05$), (Table 5).

Table 5. Effect of the interaction between fosfomycin (FOS) and *C. scolyimus* extract (CSE) on the intestinal absorptive area (IAA, μm^2) in weaned piglets¹

IAA	FOS (mg/kg)			<i>p</i> - value		
	0	300	300	FOS	CSE	FOS x CSE
Medium jejunum	5.67 ± 0.24	7.35 ± 0.46	8.44 ± 0.88	0.0034	0.0192	0.0006
Ileum	5.49 ± 0.26	6.29 ± 0.23	5.13 ± 0.31	NS	0.0296	0.0205

NS= not significant ($p > 0.05$).

¹ The effects of the mycotoxin treatments on the IAA were not significant.

301

302 Generally, the number of intestinal goblet cells increased with FOS and CSE
 303 treatments, whereas a decrease was evident in goblet cells from villi after DON
 304 treatments. Goblet cells count in crypts of ileum increased in FOS treated groups ($p=$
 305 0.0120). The treatments with CSE increased the count of these cells in villi ($p= 0.0159$)

306 and crypts ($p= 0.0143$) of medium jejunum. A negative effect of DON was observed in
307 goblet cells count in villi of medium jejunum ($p= 0.0125$) and ileum ($p= 0.0336$) (Table
308 6). No significant interactions were detected between FOS, CSE and DON on goblet
309 cells count ($p> 0.05$).

Table 6. Effect of fosfomycin (FOS), *C. scolymus* extract (CSE) and deoxynivalenol (DON) on goblet cells/100 villi and goblet cells/100 crypts in the small intestine of weaned piglets¹

Item	FOS (mg/kg)		p - value	CSE (g/ton)		p - value	DON (mg/kg)		p - value
	0	30		0	300		0	30	
<u>Medium jejunum</u>									
villi	871.69 ± 84.47	1153.33 ± 120.80	NS	886.47 ± 107.87	1114.62 ± 93.93	0.0159	1087.80 ± 103.30	882.31 ± 102.77	0.0125
crypts	1155.69 ± 78.55	1291.67 ± 86.14	NS	1095.73 ± 70.53	1350.38 ± 83.63	0.0143	1221.07 ± 82.77	1205.77 ± 85.74	NS
<u>Ileum</u>									
villi	1045.94 ± 72.8	954.58 ± 75.52	NS	947.33 ± 81.14	1075.38 ± 61.25	NS	1102.67 ± 75.37	896.15 ± 61.61	0.0336
crypts	1421.31 ± 94.7	1677.08 ± 81.43	0.012	1437.73 ± 103.07	1638.46 ± 78.63	NS	1526.73 ± 75.23	1535.77 ± 121.08	NS

NS= not significant ($p > 0.05$).

¹ Interaction between different factors was not significant ($p > 0.05$).

311 **Adherence of bacteria to the intestinal mucus**

312 Treatments with FOS, CSE and the combination of both resulted in a statistically
313 significant increase in the percentages of adhesion of bacteria to intestinal mucus ($p <$
314 0.001 , $p = 0.0133$ and $p = 0.0049$, respectively) compared to FOS and CSE free groups.
315 In the latter, the adhesion percentage of *E. coli* was 45.71%, whereas FOS or CSE
316 treated groups increased the percentage of adhesion to 83.67% and 72.75%,
317 respectively. The combination of treatments evidenced an indifferent type interaction. In
318 this case, the adhesion percentage of bacteria was 81.61%. The percentage of bacteria
319 adhered to intestinal mucus was not affected by treatments with DON ($p > 0.05$), (Table
320 7).

Table 7. Effect of the interaction between fosfomycin (FOS) and *C. scolyimus* extract (CSE) on the percentages (%) of adherence of bacteria to intestinal mucus of weaned piglets¹

Bacterial adhesion to the ileum mucus	FOS (mg/kg)		p- value				
	0	30	FOS	CSE			
CSE (g/ton)	0	300	0	300			
Adhered	45.71 ± 4.45	72.25 ± 6.42	83.67 ± 4.02	81.61 ± 6.08	<0.0001	0.0133	0.0049

¹ Mycotoxin treatments produced no significant effects on the adherence of bacteria to intestinal mucus.

321

322 Discussion

323 FOS, CSE and DON are commonly found together in the weaning diet. These
 324 compounds, individually or combined, may impact on the important morphological,

325 histological and microbiota modifications produced during weaning, affecting the
326 animals' productive outcome.

327 **Bacteria, VFAs and pH**

328 LAB populations were not affected by none of the treatments in any of the
329 intestine portions studied. Natural resistance of LAB strains to antibiotics and bile salts,
330 increased by CSE consumption, has been largely demonstrated (17,60–62). The
331 influence of mycotoxins on intestinal microbiota of pigs have been poorly investigated.
332 Available data on the interaction of mycotoxins with bacteria are mainly related to the
333 ability of the intestinal microbiota to detoxify mycotoxins (63–67,24). Results obtained
334 in a study conducted by Waché *et al.* showed that cultivable bacteria diversity in fecal
335 samples was conserved in animals that consumed feed naturally contaminated with
336 DON (2.8 mg/kg) (24). Accordingly, in our study, when piglets received diets
337 containing DON at 1mg/kg, alone or in combination with the other factors, significant
338 changes in CFU counts were neither observed for LAB nor for *Enterobacteriaceae*. In
339 addition, pH values were conserved in all gastrointestinal tract portions after DON
340 treatments. It is likely that gut bacteria possess resistance mechanisms against this
341 mycotoxin, in fact *in vitro* studies identified intestinal bacterial strains that promote
342 metabolism, binding or detoxification of DON (64,67). By contrast, VFAs
343 concentrations were lowered. The normal concentration of VFAs in the caecum varies
344 according to the content and composition of the raw material in the diet, being around
345 80 mmol/L for this stage of pig rearing (68–70). In the present study, the decrease in
346 VFAs at caecum level, where the mycotoxin is metabolized, could be explained by a
347 detrimental effect of DON on the metabolism of culture independent bacterial
348 populations as it has been previously demonstrated (17,24).

349 A lower count of *Enterobacteriaceae* population and E/L in caecum and colon
350 was observed in pigs treated with CSE. It has been recently demonstrated by our
351 research group that using CSE as feed additive substantially increases bile production in
352 pigs (15). Important bile effects on the intestinal microbiota have been described
353 involving two main mechanisms: direct detergent action on bacterial cell membranes
354 (mainly in proximal intestine) and an indirect action by interacting with specific nuclear
355 receptors (FXR, TGR 5, mainly in large intestine) and thus inducing antimicrobial
356 peptides synthesis (10,71–73). Furthermore, Cremers *et al.* indicated that bile acid salts

357 have profound effects on many key proteins in bacteria (74). Results from different
358 studies suggest that bile salts could potentially induce DNA damage through oxidative
359 stress in *E. coli* (75–79). Therefore bile acids are thought to have destructive effects on
360 gut microbes except for some bile acid tolerant bacteria. LAB can tolerate biliary acids
361 by expressing bile salts hydrolases (80). This might have contributed to lower
362 *Enterobacteriaceae* count in CSE treated groups in our study without altering LAB.

363 The administration of CSE in the piglets' diet increased the concentration of
364 butyric acid, an important energetic VFA in large intestine (81–84). This finding is in
365 agreement with other scientific studies that detected an increase in the proportion of
366 butyrate and an equal or lower concentration of acetate in diets containing other natural
367 extracts (85–90). The no significant change in the levels of acetate could be attributed to
368 the fact that butyrate producing bacteria are able to use acetate as a substrate. In this
369 way, acetic acid constitutes a type of substrate for cross-feeding interactions that occur
370 among colonic bacteria (91–95).

371 FOS reduced *Enterobacteriaceae* populations in caecum and colon exerting a
372 bactericide effect, related to its low oral bioavailability (96). LAB populations, capable
373 of resisting relatively high bactericide antibiotic concentrations through different
374 adaptive mechanisms (97,98), were not affected by FOS. Further, a reduction in pH was
375 observed in caecum and colon as consequence of the diminished E/L in FOS treated
376 groups. These findings, together with an increase of butyrate production ($p > 0.05$)
377 represent an important favorable aspect of intestinal health in weaning piglets.

378 Interactions observed between FOS and CSE treatments could be explained by a
379 possible interference of their mechanisms of action: The modes by which antimicrobial
380 intestinal peptides kill bacteria are varied. The cytoplasmic membrane is a frequent
381 target, but peptides may also interfere with DNA and protein synthesis, protein folding,
382 and cell wall synthesis. Thereby, some peptides form a complex with different cell wall
383 precursors inhibiting cell wall biosynthesis. On the other hand, FOS is transported into
384 bacteria via both glycerol-3-phosphate and hexose phosphate membrane transporter
385 systems. Besides, it interferes with the cytoplasmic step of bacterial cell wall
386 biosynthesis, the formation of the peptidoglycan precursor UDP *N*-acetylmuramic acid
387 (99–103). Interference between the action of FOS and intestinal peptides (induced by
388 biliary acids through nuclear receptors), at cytoplasmatic or membrane transporter level
389 could occur. Moreover, some cytoplasmic peptides show bacteriostatic effects that

390 could antagonize bactericidal effect of FOS that requires bacteria to grow at log phase to
391 exert it's action; i.e. antagonistic or indifference effects may be due to inhibition of
392 bacterial growth by static agents (104).

393 **Intestinal morpho-physiology**

394 Clinical symptoms characteristic of DON intoxication were not observed in the
395 animals under study. In order to evaluate intestinal health, morphological and
396 physiological integrity of intestinal mucosa was studied. The mycotoxin DON
397 administered at 1mg/Kg of feed in our experiment did not affect IAA, which is in
398 agreement with studies that indicate that higher DON concentrations are needed to
399 deteriorate the tissue at this level (105). However, in the present study, treatments with
400 DON adversely affected the number of goblet cells. Similarly, Obremski *et al.* obtained
401 a lower goblet cells count in jejunum of piglets maintained on diets contaminated with
402 DON for 14 days (106). In addition, Bracarense *et al.* and Gerez *et al.* also reported
403 lower goblet cell counts in jejunum after administration of 1.5 to 3 mg/kg DON
404 respectively in the diet of animals during 4 to 5 weeks (107,108). Apart from a lower
405 goblet cells count, a lower expression of mucins (mainly MUC1, MUC2 and MUC3) by
406 these cells would be expected after the ingestion of low DON concentrations (109–111).
407 In our study this effect was reflected by a lower adherence of *E. coli* to mucus ($p > 0.05$;
408 data not shown). Moreover, disaccharidases activity decreased with DON treatments,
409 particularly maltase and sucrose, in the different portions of the intestine. The
410 undesirable effect of the mycotoxin could be a consequence of its mechanism of action
411 as a potent inhibitor of protein synthesis, including the synthesis of disaccharidases (21).

412 After FOS treatments, IAA and goblet cells were considerably increased. In a
413 previous study, Pérez Gaudio *et al.* demonstrated a protective effect of the antibiotic
414 FOS on in vitro cell cultures that would favor a trophic effect on intestinal mucosa
415 (112). On the other hand, certain antibiotics modulate physiological inflammation
416 decreasing the catabolic cost of maintaining immune response, thereby favoring
417 mucosal anabolic processes (113–117). A greater goblet cells count improved mucus
418 production which was revealed by a greater pathogenic bacterial adhesion. Enzymatic
419 activity was also increased in FOS treated groups, being maltase the most active
420 disaccharidase, as expected for the age and diet of the animals (118).

421 CSE as an additive in the diet significantly increased IAA and goblet cells.
422 These findings are consistent with previous works which reported that using different
423 sources of natural extracts increased villi height and villi: crypts ratio in the small
424 intestine of weaned piglets (95,119,120). In pigs, the action of bile acids on the G
425 protein-coupled bile acid receptor (TGR5) found in enteroendocrine cells stimulates
426 secretion of glucagon like peptides (GLP)-1 and 2, which function respectively as the
427 major incretin hormone involved in glucose homeostasis and key trophic hormone in
428 intestinal adaptation and growth in response to food ingestion. In fact, the induction of
429 GLP-2 secretion, by TGR 5, is involved in the trophic action of bile acids in the
430 intestinal lumen (121,122). The observed increase in IAA and goblet cells in our study
431 could be explained by the direct trophic effect of the increased bile production (73,123)
432 when CSE is added to the diet. As stated before, the increased bacterial adherence to
433 mucus would be a direct consequence of the increased number of goblet cells rendering
434 a better mucus quality. Maltase activity, which plays an important role at weaning, was
435 increased in CSE treated groups at ileum level. This could be related to the trophic
436 effect of bile acids, augmented after CSE administration, in this portion of the intestine
437 through interaction with specific nuclear receptors (10,12,73,124).

438 Beneficial effects observed after co-administration of FOS and CSE on IAA and
439 bacterial adherence to mucus did not exceed the benefits of individual treatments
440 (antagonistic or indifferent interactions). It could be possible that anti-inflammatory
441 mechanisms exerted by FOS and biliary acids, that involve cytokines produced by
442 intestine immune cells, interfere at different levels (117,125–135).

443 **Conclusions**

444 The gastrointestinal mucosa is the first biological barrier that makes contact to
445 different compounds present in feed, and consequently, it could be exposed to dietary
446 toxins. Thereby the intestinal epithelial cells are target for antibiotic, natural extracts
447 used as additives and mycotoxins.

448 In the present study, we have demonstrated the impact of FOS, CSE and DON
449 on intestinal health parameters. DON showed a deleterious effect at different levels of
450 the intestinal epithelium at sub-toxic concentrations. This could represent a
451 predisposing factor to progressive weight loss, digestive problems and diarrhea as well
452 as a reduction in the intestinal barrier function.

453 The antibiotic FOS and CSE improved all studied parameters in relation with the
454 intestinal health. Interactions between both treatments resulted in similar beneficial
455 effects as the individual administration, there remains work to be done investigating the
456 specific mechanisms which contribute to this type of interactions.

457 Finally, the knowledge of the intestinal effects of these compounds contributes
458 to understand the physiological/physio-pathological gut changes and their potential
459 productive consequences. Particularly, CSE could be considered as a nutritional strategy
460 to prevent enteric disorders and improve intestinal health in post-weaned piglets,
461 emerging as a possible alternative to preventive use of antibiotics. In addition, the
462 presence of mycotoxins in feed even at sub-toxic concentrations may cause detrimental
463 gastrointestinal effects and should not be underestimated.

464

465 **Acknowledgements**

466 This work was supported by Consejo Nacional de Investigaciones Científicas y
467 Técnicas (PICT 2012- 2398) from Argentina.

468 The authors would like to thank Edgardo Rodriguez and Sandra E. Pérez for
469 collaborating with this study.

470

471 **References**

- 472 1. Hampson DJ, Kidder DE. Influence of creep feeding and weaning on brush
473 border enzyme activities in the piglet small intestine. *Res Vet Sci.* 1986;40(1):
474 24–31.
- 475 2. Lallès J, Bosi P, Smidt H, Stokes CR. Weaning — A challenge to gut
476 physiologists. *Livest Sci.* 2007;108: 82–93.
- 477 3. Heo JM, Opapeju FO, Pluske JR, Kim JC, Hampson DJ, Nyachoti CM.
478 Gastrointestinal health and function in weaned pigs: a review of feeding
479 strategies to control post-weaning diarrhoea without using in-feed antimicrobial
480 compounds. *J Anim Physiol Anim Nutr.* 2013;97: 207–237.
- 481 4. Martineau G-P, Morvan H. *Maladies d'élevage des porcs: diagnostics, causes,*
482 *traitements.* France Agricole Editions; 2010.

- 483 5. Schiavone A, Righi F, Quarantelli A, Bruni R, Serventi P, Fusari A. Use of
484 *Silybum marianum* fruit extract in broiler chicken nutrition: influence on
485 performance and meat quality. 2007;91: 256–262.
- 486 6. Abbasi F, Samadi F. Effect of Different Levels of Artichoke (*Cynara scolymus*
487 L.) Leaf Powder on the Performance and Meat Quality of Japanese Quail. *Poult*
488 *Sci J*. 2014;2(2): 95–111.
- 489 7. Martínez D, Uculmana C. Artichoke extract (*Cynara scolymus* L.): experiences
490 of use in animal production markets and opportunities for its production in Peru.
491 *Agroindustrial Sci*. 2016;1: 155–161.
- 492 8. Saeed M, Babazadeh D, Arif M, Arain MA, Bhutto ZA, Shar AH, et al.
493 *Silymarin*: a potent hepatoprotective agent in poultry industry. *Worlds Poult Sci*
494 *J*. 2017;73(3): 483–492.
- 495 9. Bertók L. Bile acids in physico-chemical host defence. *Pathophysiology*.
496 2004;11(3): 139–145.
- 497 10. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation
498 of antibacterial defense in the small intestine by the nuclear bile acid receptor.
499 *Proc Natl Acad Sci USA*. 2006;103(10): 3920–3925.
- 500 11. Mikov M, Fawcett J, Kuhajda K, Kevresan S. Pharmacology of Bile Acids and
501 their Derivatives: Absorption Promoters and Therapeutic Agents. *Eur J drug*.
502 2006;31(3): 237–251.
- 503 12. Chiang JYL. Bile acids: regulation of synthesis. *J Lipid Res*. 2009;50(10): 1955–
504 1966.
- 505 13. Speroni E, Cervellati R, Govoni P, Guizzardi S, Renzulli C, Guerra MC. Efficacy
506 of different *Cynara scolymus* preparations on liver complaints. *J*
507 *Ethnopharmacol*. 2003;86: 203–211.
- 508 14. Wegener T, Fintelmann V. Pharmacological properties and therapeutic profile of
509 artichoke (*Cynara scolymus* L.). *Wien Med Wochenschr*. 1999;149(8–10): 241–
510 247.
- 511 15. Martínez G, Diéguez SN, Rodríguez E, Decundo JM, Romanelli A, Fernández
512 Paggi MB, et al. Effect of *Cynara scolymus* and *Silybum marianum* extracts on

- 513 bile production in pigs. *J Appl Anim Res.* 2018;46(1): 1059–1063.
- 514 16. Rotter BA. Invited review: Toxicology of deoxynivalenol (vomitoxin). *J Toxicol*
515 *Environ Heal Part A.* 1996;48(1): 1–34.
- 516 17. Piotrowska, K. Śliżewska, A. Nowak, Ł. Zielonka, Z. Żakowska, M. Gajęcka
517 MG. The Effect of Experimental Fusarium Mycotoxicosis on Microbiota
518 Diversity in Porcine Ascending Colon Contents. *Toxins (Basel).* 2014;6: 2064–
519 2081.
- 520 18. Vesonder RF, Ciegler A, Jensen AH. Isolation of the emetic principle from
521 *Fusarium*-infected corn. *Appl Microbiol.* 1973;26(6): 1008–1010.
- 522 19. Eriksen GS, Pettersson H. Toxicological evaluation of trichothecenes in animal
523 feed. *Anim Feed Sci Technol.* 2004;114: 205–239.
- 524 20. Lawlor PG, Lynch PB. peer reviewed Mycotoxins in pig feeds 2: clinical
525 aspects. *Ir Vet J.* 2001;54(4): 172–176.
- 526 21. Pestka JJ. Deoxynivalenol : Toxicity , mechanisms and animal health risks. *Anim*
527 *Feed Sci Technol.* 2007;137: 283–298.
- 528 22. Alizadeh A, Braber S, Akbari P, Garssen J, Fink-gremmels J. Deoxynivalenol
529 Impairs Weight Gain and Affects Markers of Gut Health after Low-Dose, Short-
530 Term Exposure of Growing Pigs. *Toxins (Basel).* 2015;7: 2071–2095.
- 531 23. Roigé MB, Aranguren SM, Riccio MB, Pereyra S, Soraci AL, Tapia MO.
532 Mycobiota and mycotoxins in fermented feed, wheat grains and corn grains in
533 Southeastern Buenos Aires Province, Argentina. *Rev Iberoam Micol.* 2009;26(4):
534 233–237.
- 535 24. Waché YJ, Valat C, Postollec G, Bougeard S, Burel C, Oswald IP, et al. Impact
536 of deoxynivalenol on the intestinal microflora of pigs. *Int J Mol Sci.* 2009;10(1):
537 1–17.
- 538 25. Castillo M, Martín-Orúe SM, Anguita M, Pérez JF, Gasa J. Adaptation of gut
539 microbiota to corn physical structure and different types of dietary fibre. *Livest*
540 *Sci.* 2007;109(1–3): 149–152.
- 541 26. Han KS, Balan P, Molist Gasa F, Boland M. Green kiwifruit modulates the

- 542 colonic microbiota in growing pigs. *Lett Appl Microbiol.* 2011;52(4): 379–385.
- 543 27. O’Shea CJ, Sweeney T, Lynch MB, Callan JJ, O’Doherty J V. Modification of
544 selected bacteria and markers of protein fermentation in the distal gastrointestinal
545 tract of pigs upon consumption of chitosan is accompanied by heightened manure
546 odor emissions. *J Anim Sci.* 2011;89(5): 1366–1375.
- 547 28. Chen K, Gao J, Li J, Huang Y, Luo X, Zhang T. Effects of probiotics and
548 antibiotics on diversity and structure of intestinal microflora in broiler chickens.
549 *African J Microbiol Res.* 2012;6(37): 6612–6617.
- 550 29. Macconkey AT. Note on a New Medium for the Growth and Differentiation of
551 the *Bacillus Coli Communis* and the *Bacillus Typhi Abdominalis*. *Lancet.*
552 1900;156(4010): 20.
- 553 30. De Man JC, Rogosa M, Sharpe ME. A medium used for the cultivation of
554 *Lactobacilli*. *J Appl Bacteriol.* 1960;23: 130–135.
- 555 31. White LA, Newman MC, Cromwell GL, Lindemann MD. Brewers dried yeast as
556 a source of mannan oligosaccharides for weanling pigs. *J Anim Sci.* 2002;80(10):
557 2619–2628.
- 558 32. Mikkelsen LL, Jensen BB. Effect of fructo-oligosaccharides and transgalacto-
559 oligosaccharides on microbial populations and microbial activity in the
560 gastrointestinal tract of piglets post-weaning. *Anim Feed Sci Technol.*
561 2004;117(1–2): 107–119.
- 562 33. Jouany JP. Volatile fatty acid and alcohol determination in digestive contents,
563 silage juices, bacterial cultures and anaerobic fermentor contents. *Sci Aliments.*
564 1982; 2: 131–144.
- 565 34. Pluske JR, Thompson MJ, Atwood CS, Bird PH, Williams IH, Hartmann PE.
566 Maintenance of villus height and crypt depth, and enhancement of disaccharide
567 digestion and monosaccharide absorption, in piglets fed on cows’ whole milk
568 after weaning. *Br J Nutr.* 1996;76: 409–422.
- 569 35. Awad WA, Ghareeb K, Paßlack N, Zentek J. Dietary inulin alters the intestinal
570 absorptive and barrier function of piglet intestine after weaning. *Res Vet Sci.*
571 2013;95(1): 249–254.

- 572 36. Solaymani-Mohammadi S, Singer SM. Host Immunity and Pathogen Strain
573 Contribute to Intestinal Disaccharidase Impairment following Gut Infection. *J*
574 *Immunol.* 2011;187(7): 3769–3775.
- 575 37. Bradford MM. A rapid and sensitive method for the quantitation of microgram
576 quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.*
577 1976;72(1–2): 248–254.
- 578 38. Dahlqvist A. Method for Assay of Intestinal Disaccharidases. *Anal Biochem*
579 1964;7: 18–25.
- 580 39. Grant AL, Thomas JW, King KJ, Liesman JS. Effects of dietary amines on the
581 small intestinal variables in neonatal pigs fed soy protein isolate. *J Anim Sci.*
582 1990;68: 363–371.
- 583 40. Pluske JR, Williams IH, Aherne FX. Villous height and crypt depth in piglets in
584 response to increases in the intake of cows' milk after weaning. *Anim Sci.*
585 1996;62(1): 145–158.
- 586 41. van Beers-Schreurs HM, Nabuurs MJ, Vellenga L, Kalsbeek-van der Valk HJ,
587 Wensing T, Breukink HJ. Weaning and the weanling diet influence the villous
588 height and crypt depth in the small intestine of pigs and alter the concentrations
589 of short-chain fatty acids in the large intestine and blood. *J Nutr.* 1998;128(6):
590 947–953.
- 591 42. Spreeuwenberg MA, Verdonk JM, Gaskins HR, Verstegen MW. Small intestine
592 epithelial barrier function is compromised in pigs with low feed intake at
593 weaning. *J Nutr.* 2001; 131(5): 1520–1527.
- 594 43. Montagne L, Pluske JR, Hampson DJ. A review of interactions between dietary
595 fibre and the intestinal mucosa, and their consequences on digestive health in
596 young non-ruminant animals. *Anim Feed Sci Technol.* 2003;108(1–4): 95–117.
- 597 44. Budiño FEL, Thomaz MC, Kronka RN, Nakaghi LSO, Tucci FM, Fraga AL, et
598 al. Effect of probiotic and prebiotic inclusion in weaned piglet diets on structure
599 and ultra-structure of small intestine. *Brazilian Arch Biol Technol.* 2005;48(6):
600 921–929.
- 601 45. Hedemann MS, Eskildsen M, Lærke HN, Pedersen C, Lindberg JE, Laurinen P,

- 602 et al. Intestinal morphology and enzymatic activity in newly weaned pigs fed
603 contrasting fiber concentrations and fiber properties. *J Anim Sci.* 2006;84(6):
604 1375–1386.
- 605 46. Awad WA, Ghareeb K, Abdel-Raheem S, Bohm J. Effects of dietary inclusion of
606 probiotic and synbiotic on growth performance, organ weights, and intestinal
607 histomorphology of broiler chickens. *Poult Sci.* 2009;88(1): 49–56.
- 608 47. Xu ZR, Hu CH, Xia MS, Zhan XA, Wang MQ. Effects of dietary
609 fructooligosaccharide on digestive enzyme activities, and intestinal microflora
610 and morphology of male broilers. *Poult Sci.* 2003;82: 1030–1036.
- 611 48. Buddle JR, Bolton JR. The pathophysiology of diarrhoea in pigs. *Pig News Inf.*
612 1992;13: 41–45.
- 613 49. Burrin DG, Stoll B, Van Goudoever JB, Reeds PJ. 19 Nutrient Requirements for
614 Intestinal Growth and Metabolism in the Developing Pig. In: *Digestive
615 Physiology of Pigs: Proceedings of the 8th Symposium.* CABI; 2001. p. 75.
- 616 50. Kisielinski K, Willis S, Prescher a, Klosterhalfen B, Schumpelick V. A simple
617 new method to calculate small intestine absorptive surface in the rat. *Clin Exp
618 Med.* 2002;2(3): 131–135.
- 619 51. Piel C, Montagne L, Sève B, Lallès J-P. Increasing digesta viscosity using
620 carboxymethylcellulose in weaned piglets stimulates ileal goblet cell numbers
621 and maturation. *J Nutr.* 2005;135(1): 86–91.
- 622 52. Wadolowski EA, Laux DC, Cohen PS. Colonization of the Streptomycin-
623 Treated Mouse Large-Intestine by A Human Fecal Escherichia-Coli Strain - Role
624 of Growth in Mucus. *Infect Immun.* 1988;56(5): 1030–1035.
- 625 53. Edelman S, Leskelä S, Ron E, Apajalahti J, Korhonen TK. In vitro adhesion of an
626 avian pathogenic Escherichia coli O78 strain to surfaces of the chicken intestinal
627 tract and to ileal mucus. *Vet Microbiol.* 2003;91(1): 41–56.
- 628 54. Blomberg L, Krivan HC, Cohen PS, Conway PL. Piglet ileal mucus contains
629 protein and glycolipid (galactosylceramide) receptors specific for Escherichia
630 coli K88 fimbriae. *Infect Immun.* 1993;61(6): 2526–2531.
- 631 55. Blomberg L, Gustafsson L, Cohen PS, Conway PL, Blomberg A. Growth of

- 632 Escherichia coli K88 in piglet ileal mucus: Protein expression as an indicator of
633 type of metabolism. *J Bacteriol.* 1995;177(23): 6695–6703.
- 634 56. Pestova MI, Clift RE, Jason Vickers R, Franklin MA, Mathew AG. Effect of
635 weaning and dietary galactose supplementation on digesta glycoproteins in pigs.
636 *J Sci Food Agric.* 2000;80(13): 1918–1924.
- 637 57. Mathew A. Seeking Alternatives to Growth Promoting Antibiotics Alan.
638 *Manitoba Swine Semin.* 2002;16: 115–128.
- 639 58. Erdem AL, Avelino F, Xicohtencatl-Cortes J, Girón JA. Host protein binding and
640 adhesive properties of H6 and H7 flagella of attaching and effacing *Escherichia*
641 *coli.* *J Bacteriol.* 2007;189(20): 7426–7435.
- 642 59. Bai X, Liu X, Su Y. Inhibitory effects of intestinal mucus on bacterial adherence
643 to cultured intestinal epithelial cells after surface burns. *Chin Med J.*
644 2000;113(5): 449–450.
- 645 60. Korhonen J. Antibiotic Resistance of Lactic Acid Bacteria. PhD Thesis. 2010. 1-
646 75 p.
- 647 61. Dowarah R, Verma AK, Agarwal N. The use of *Lactobacillus* as an alternative of
648 antibiotic growth promoters in pigs: A review. *Anim Nutr.* 2017;3(1): 1–6.
- 649 62. Liao SF, Nyachoti M. Using probiotics to improve swine gut health and nutrient
650 utilization. *Anim Nutr.* 2017;3(4): 331–343.
- 651 63. He P, Young LG, Forsberg C. Microbial transformation of deoxynivalenol
652 (vomitoxin). *Appl Environ Microbiol.* 1992;58(12): 3857–3863.
- 653 64. Kollarczik B, Gareis M, Hanelt M. In Vitro Transformation of the *Fusarium*
654 *Mycotoxins Deoxynivafenof and Zearafenone by the Normal Gut Microflora of*
655 *Pigs Birgit.* *Nat Toxins.* 1994;2: 105–110.
- 656 65. Eriksen GS, Pettersson H, Johnsen K, Lindberg JE. Transformation of
657 trichothecenes in ileal digesta and faeces from pigs. *Arch Tierernahr.* 2002;56(4):
658 263–274.
- 659 66. Niderkorn V, Boudra H, Morgavi DP. Binding of *Fusarium* mycotoxins by
660 fermentative bacteria in vitro. *J Appl Microbiol.* 2006;101(4): 849–856.

- 661 67. Young JC, Zhou T, Yu H, Zhu H, Gong J. Degradation of trichothecene
662 mycotoxins by chicken intestinal microbes. *Food Chem Toxicol.* 2007;45(1):
663 136–43.
- 664 68. Sauer WC, Mosenthin R, Hartog L a Den. The effect of source of fiber on ileal
665 and fecal amino acid digestibility and bacterial nitrogen excretion in growing
666 pigs . *J Anim Sci.* 1991;69: 4070–4077.
- 667 69. Knudsen KEB, Jensen BB, Hansen I. Digestion of polysaccharides and other
668 major components in the small and large intestine of pigs fed on diets consisting
669 of oat fractions rich in β -D-glucan. *Br J Nutr.* 1993;70(2): 537–556.
- 670 70. Freire JPB, Guerreiro AJG, Cunha LF, Aumaitre A. Effect of dietary fibre source
671 on total tract digestibility, caecum volatile fatty acids and digestive transit time in
672 the weaned piglet. *Anim Feed Sci Technol.* 2000;87(1–2): 71–83.
- 673 71. D’Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, Wendum D, Firrincieli D,
674 Coilly A, et al. Bile Salts Control the Antimicrobial Peptide Cathelicidin Through
675 Nuclear Receptors in the Human Biliary Epithelium. *Gastroenterology.*
676 2009;136(4): 1435–1443.
- 677 72. Nie Y, Hu J, Yan X. Cross-talk between bile acids and intestinal microbiota in
678 host metabolism and health. *J Zhejiang Univ B.* 2015;16(6): 436–446.
- 679 73. Burrin D, Stoll B, Moore D. Digestive physiology of the pig symposium:
680 Intestinal bile acid sensing is linked to key endocrine and metabolic signaling
681 pathways. *J Anim Sci.* 2013;91(5): 1991–2000.
- 682 74. Cremers CM, Knoefler D, Vitvitsky V, Banerjee R, Jakob U. Bile salts act as
683 effective protein-unfolding agents and instigators of disulfide stress in vivo. *Proc*
684 *Natl Acad Sci.* 2014;111(16): E1610–E1619.
- 685 75. Kandell RL, Bernstein C. Bile salt/acid induction of DNA damage in bacterial
686 and mammalian cells: implications for colon cancer. *Nutr Cancer.* 1991; 16(3–4):
687 227–238.
- 688 76. Bernstein H, Payne CM, Bernstein C, Schneider J, Beard SE, Crowley CL.
689 Activation of the promoters of genes associated with DNA damage, oxidative
690 stress, ER stress and protein malfolding by the bile salt, deoxycholate. *Toxicol*

- 691 Lett. 1999;108(1): 37–46.
- 692 77. Bernstein C, Bernstein H, Payne CM, Beard SE, Schneider J. Bile salt activation
693 of stress response promoters in *Escherichia coli*. *Curr Microbiol.* 1999;39(2): 68–
694 72.
- 695 78. Chou JH, Greenberg JT, Demple B. Posttranscriptional repression of *Escherichia*
696 *coli* OmpF protein in response to redox stress: positive control of the micF
697 antisense RNA by the soxRS locus. *J Bacteriol.* 1993;175(4): 1026–1031.
- 698 79. Oh JT, Cajal Y, Skowronska EM, Belkin S, Chen J, Van Dyk TK, et al. Cationic
699 peptide antimicrobials induce selective transcription of micF and osmY in
700 *Escherichia coli*. *Biochim Biophys Acta.* 2000;1463(1): 43–54.
- 701 80. Begley M, Gahan CGM, Hill C. The interaction between bacteria and bile. *FEMS*
702 *Microbiol Rev.* 2005;29(4): 625–651.
- 703 81. Bederska-Lojewska D, Pieszka M. Modulating gastrointestinal microflora of pigs
704 through nutrition using feed additives. *Ann Anim Sci.* 2011;11(3): 333–355.
- 705 82. Steer T.; Carpenter H.; Tuohy K.; Gibson G.R. Perspectives on the role of the
706 human gut microbiota and its modulation by pro- and prebiotics. *Nutr Res Rev.*
707 2000;13(2000): 229–254.
- 708 83. Samanta AK, Jayapal N, Senani S, Kolte AP, Sridhar M. Prebiotic inulin: Useful
709 dietary adjuncts to manipulate the livestock gut microflora. *Brazilian J Microbiol.*
710 2013;44(1): 1–14.
- 711 84. Blottière HM, Buecher B, Galmiche J-P, Cherbut C. Molecular analysis of the
712 effect of short-chain fatty acids on intestinal cell proliferation. *Proc Natl Acad*
713 *Sci.* 2003;62: 101–106.
- 714 85. Levrat M-A, Rémésy C, Demigné C. High propionic acid fermentations and
715 mineral accumulation in the cecum of rats adapted to different levels of inulin. *J*
716 *Nutr.* 1991;121(11): 1730–1737.
- 717 86. Campbell JM, Fahey GC, Wolf BW. Nutrient Metabolism Selected Indigestible
718 Oligosaccharides Affect Large Bowel Mass, Cecal and Fecal Short-Chain Fatty
719 Acids, pH and Microflora in Rats 1,2. *J Nutr.* 1997;127: 130–136.

- 720 87. Kleessen B, Hartmann L, Blaut M. Oligofructose and long-chain inulin: influence
721 on the gut microbial ecology of rats associated with a human faecal flora. *Br J*
722 *Nutr.* 2001;86(2): 291–300.
- 723 88. Poulsen M, Mølck A, Jacobsen BL. Different effects of short- and long-chained
724 fructans on large intestinal physiology and carcinogen-induced aberrant crypt
725 foci in rats. *Nutr Cancer.* 2002;42: 194–205.
- 726 89. Gibson GR, Probert HM, Loo J Van, Rastall RA, Roberfroid MB. Dietary
727 modulation of the human colonic microbiota: updating the concept of prebiotics.
728 *Nutr Res Rev.* 2004;17(2): 259–275.
- 729 90. Loh G, Eberhard M, Brunner RM, Hennig U, Kuhla S, Kleessen B, et al. Inulin
730 alters the intestinal microbiota and short-chain fatty acid concentrations in
731 growing pigs regardless of their basal diet. *J Nutr.* 2006;136(5): 1198–1202.
- 732 91. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al.
733 Phylogenetic relationships of butyrate-producing bacteria from the human gut.
734 *Appl Environ Microbiol.* 2000;66(4): 1654–1661.
- 735 92. Duncan SH, Holtrop G, Lobley GE, Calder AG, Stewart CS, Flint HJ.
736 Contribution of acetate to butyrate formation by human faecal bacteria. *Br J Nutr.*
737 2004;91(6):915–923.
- 738 93. Mølbak L, Thomsen LE, Jensen TK, Bach Knudsen KE, Boye M. Increased
739 amount of *Bifidobacterium thermacidophilum* and *Megasphaera elsdenii* in the
740 colonic microbiota of pigs fed a swine dysentery preventive diet containing
741 chicory roots and sweet lupine. *J Appl Microbiol.* 2007;103(5): 1853–1867.
- 742 94. Patterson JK, Yasuda K, Welch RM, Miller DD, Lei XG. Supplemental Dietary
743 Inulin of Variable Chain Lengths Alters Intestinal Bacterial Populations in
744 Young Pigs. *J Nutr.* 2010;140(12): 2158–2161.
- 745 95. Liu H, Ivarsson E, Dicksved J, Lundh T, Lindberg JE. Inclusion of Chicory
746 (*Cichorium intybus* L.) in pigs' diets affects the intestinal microenvironment and
747 the gut microbiota. *Appl Environ Microbiol.* 2012;78(12): 4102–4109.
- 748 96. Pérez D, Soraci A, Tapia M. Pharmacokinetics and bioavailability of calcium
749 fosfomycin in post weaning piglets after oral administration. *Int J Agro Vet Med*

- 750 Sci. 2012;6(6): 424–435.
- 751 97. Bernier SP, Surette MG. Concentration-dependent activity of antibiotics in
752 natural environments. *Front Microbiol.* 2013;4: 1–14.
- 753 98. Munita JM, Arias CA, Unit AR, Santiago A De. HHS Public Access. *Mech*
754 *Antibiot Resist.* 2016;4(2): 1–37.
- 755 99. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. the Mechanism of Action of
756 Fosfomycin (Phosphonomycin). *Ann N Y Acad Sci.* 1974;235(1): 364–386.
- 757 100. Gobernado M. Revisión Fosfomicina. *Rev Española Quimioter.* 2003;16(1): 15–
758 40.
- 759 101. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J. The glycerol-3-
760 phosphate permease GlpT is the only fosfomycin transporter in *Pseudomonas*
761 *aeruginosa*. *J Bacteriol.* 2009;191(22): 6968–6974.
- 762 102. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend?
763 *Eur J Clin Microbiol Infect Dis.* 2010;29(2): 127–142.
- 764 103. Pérez DS, Tapia MO, Soraci AL. Fosfomycin: Uses and potentialities in
765 veterinary medicine. *open Vet J.* 2014;4(1): 26–43.
- 766 104. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide
767 structures and their modes of action. *Trends Biotechnol.* 2011;29(9): 464–472.
- 768 105. Grenier B, Applegate TJ. Modulation of intestinal functions following mycotoxin
769 ingestion: Meta-analysis of published experiments in animals. *Toxins.* 2013;5(2):
770 396–430.
- 771 106. Obremski K, Zielonka L, Gajecka M, Jakimiuk E, Bakula T, Baranowski M, et
772 al. Histological estimation of the small intestine wall after administration of feed
773 containing deoxynivalenol, T-2 toxin and zearalenone in the pig. *Pol J Vet Sci.*
774 2008;11(4): 339–345.
- 775 107. Bracarense A-PFL, Lucioli J, Grenier B, Drociunas Pacheco G, Moll W-D,
776 Schatzmayr G, et al. Chronic ingestion of deoxynivalenol and fumonisin, alone or
777 in interaction, induces morphological and immunological changes in the intestine
778 of piglets. *Br J Nutr.* 2012;107(12): 1776–1786.

- 779 108. Gerez JR, Pinton P, Callu P, Grosjean F, Oswald IP, Bracarense AP, aula FL.
780 Deoxynivalenol alone or in combination with nivalenol and zearalenone induce
781 systemic histological changes in pigs. *Exp Toxicol Pathol*. 2015;67(2): 89–98.
- 782 109. Laparra JM, Sanz Y. Comparison of in vitro models to study bacterial adhesion
783 to the intestinal epithelium. *Lett Appl Microbiol*. 2009;49(6): 695–701.
- 784 110. Pinton P, Graziani F, Pujol A, Nicoletti C, Paris O, Ernouf P, et al.
785 Deoxynivalenol inhibits the expression by goblet cells of intestinal mucins
786 through a PKR and MAP kinase dependent repression of the resistin-like
787 molecule β . *Mol Nutr Food Res*. 2015;59(6): 1076–1087.
- 788 111. Robert H, Payros D, Pinton P, Théodorou V, Mercier-Bonin M, Oswald IP.
789 Impact of mycotoxins on the intestine: are mucus and microbiota new targets? *J*
790 *Toxicol Environ Heal - Part B Crit Rev*. 2017;20(5): 249–275.
- 791 112. Pérez Gaudio DS, Martínez G, Fernández Paggi MB, Riccio MB, Decundo JM,
792 Diéguez S, et al. Protective Effect of Fosfomycin on Deoxynivalenol- Treated
793 Cell Cultures. *Eur J Biomed Pharm Sci*. 2016;3(7): 99–106.
- 794 113. Niewold TA. The nonantibiotic anti-inflammatory effect of antimicrobial growth
795 promoters, the real mode of action? A hypothesis. *Poult Sci*. 2007;86:605–609.
- 796 114. Costa E, Uwiera RR, Kastelic JP, Selinger LB, Inglis GD. Non-therapeutic
797 administration of a model antimicrobial growth promoter modulates intestinal
798 immune responses. *Gut Pathog*. 2011;3(1): 1–15.
- 799 115. Niewold TA. Mechanisms of antibiotics: how do they really work. *Banff Pork*
800 *Semin Proceedings, Banff, Alberta, Canada, 15-17 January 2013*. 2013;24(2013):
801 103–106.
- 802 116. Brown K, Zaytsoff SJM, Uwiera RRE, Inglis GD. Antimicrobial growth
803 promoters modulate host responses in mice with a defined intestinal microbiota.
804 *Sci Rep*. 2016;6: 1–13.
- 805 117. Brown K, Uwiera RRE, Kalmokoff ML, Brooks SPJ, Inglis GD. Antimicrobial
806 growth promoter use in livestock: a requirement to understand their modes of
807 action to develop effective alternatives. *Int J Antimicrob Agents*. 2017; 49(1):
808 12–24.

- 809 118. Collington GK, Parker DS, Armstrong DG. The influence of inclusion of either
810 an antibiotic or a probiotic in the diet on the development of digestive enzyme
811 activity in the pig. *Br J Nutr.* 1990;64(1): 59–70.
- 812 119. Touchette KJ, Carroll JA, Allee GL, Matteri RL, Dyer CJ, Beausang LA, et al.
813 Effect of spray-dried plasma and lipopolysaccharide exposure on weaned pigs : I
814 . Effects on the immune axis of weaned pigs . K J Touchette , J A Carroll , G L
815 Allee , R L Matteri , C J Dyer , L A Beausang and M E Zannelli The online
816 version of this artic. *J Anim Sci.* 2002;80: 494–501.
- 817 120. Liu P, Piao XS, Kim SW, Wang L, Shen YB, Lee HS, et al. Effects of chito-
818 oligosaccharide supplementation on the growth performance, nutrient
819 digestibility, intestinal morphology, and fecal shedding of and in weaning pigs. *J*
820 *Anim Sci.* 2008;86(10): 2609–2618.
- 821 121. le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, et al. Gut
822 Hypertrophy After Gastric Bypass Is Associated With Increased Glucagon-Like
823 Peptide 2 and Intestinal Crypt Cell Proliferation. *Ann Surg.* 2010;252(1): 50–56.
- 824 122. Jain AK, Stoll B, Burrin DG, Holst JJ, Moore DD. Enteral bile acid treatment
825 improves parenteral nutrition-related liver disease and intestinal mucosal atrophy
826 in neonatal pigs. *AJP Gastrointest Liver Physiol.* 2012;302(2): G218–G224.
- 827 123. de Diego-Cabero N, Mereu A, Menoyo D, Holst JJ, Ipharraguerre IR. Bile acid
828 mediated effects on gut integrity and performance of early-weaned piglets. *BMC*
829 *Vet Res.* 2015;11(1): 1–8.
- 830 124. Stojancevic M, Stankov K, Mikov M. The impact of farnesoid X receptor
831 activation on intestinal permeability in inflammatory bowel disease. *Can J*
832 *Gastroenterol.* 2012;26(9): 631–637.
- 833 125. Morikawa K, Oseko F, Morikawa S, Sawada M. Immunosuppressive activity of
834 fosfomycin on human T-lymphocyte function in vitro. *Antimicrob Agents*
835 *Chemother.* 1993;37(12): 2684–2687.
- 836 126. Perez Fernandez P, Herrera I, Martinez P, Gomez-Lus ML, Prieto J.
837 Enhancement of the susceptibility of *Staphylococcus aureus* to phagocytosis after
838 treatment with fosfomycin compared with other antimicrobial agents.
839 *Chemotherapy.* 1995;41(1): 45–49.

- 840 127. Krause R, Patruta S, Daxböck F, Fladerer P, Wenisch C. The effect of
841 fosfomycin on neutrophil function. *J Antimicrob Chemother.* 2001;47(2): 141–
842 146.
- 843 128. Morikawa K, Zhang J, Nonaka M, Morikawa S. Modulatory effect of macrolide
844 antibiotics on the Th1- and Th2-type cytokine production. *Int J Antimicrob*
845 *Agents.* 2002;19(1): 53–59.
- 846 129. Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, et al. Role of
847 fosfomycin tromethamine in modulating non-specific defence mechanisms in
848 chronic uremic patients towards ESBL-producing *Escherichia coli*. *Int J*
849 *Immunopathol Pharmacol.* 2008;21(1): 153–160.
- 850 130. Buret AG. Immuno-modulation and anti-inflammatory benefits of antibiotics:
851 The example of tilmicosin. *Can J Vet Res.* 2010;74(1): 1–10.
- 852 131. Shen YB, Piao XS, Kim SW, Wang L, Liu P, Yoon I, et al. Effects of yeast
853 culture supplementation on growth performance, intestinal health, and immune
854 response of nursery pigs. *J Anim Sci.* 2009;87(8) :2614–2624.
- 855 132. Yokota SI, Okabayashi T, Yoto Y, Hori T, Tsutsumi H, Fujii N. Fosfomycin
856 suppresses RS-virus-induced *Streptococcus pneumoniae* and *Haemophilus*
857 *influenzae* adhesion to respiratory epithelial cells via the platelet-activating factor
858 receptor. *FEMS Microbiol Lett.* 2010;310(1): 84–90.
- 859 133. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. *Int J*
860 *Infect Dis.* 2011;15(11): e732–e739.
- 861 134. Zhang Y, Limaye PB, Renaud HJ, Klaassen CD. Effect of various antibiotics on
862 modulation of intestinal microbiota and bile acid profile in mice. *Toxicol Appl*
863 *Pharmacol.* 2014;277(2): 138–145.
- 864 135. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. *Clin*
865 *Microbiol Rev.* 2016;29(2): 321–347.
- 866